Investment Thesis — Kenvue Inc.
The market overstates Kenvue's post-spin stagnation, missing the embedded pricing power and margin resilience of its core brands amid consumer trade-downs. Investors are extrapolating recent weak sentiment and legal overhangs, ignoring the company's ability to reaccelerate organic growth as supply chains normalize.
Catalysts
- Resolution or favorable settlement of major litigation overhangs
- Sustained margin improvement from easing input costs
- New product launches or successful brand extensions in OTC/personal care
Risk Factors
- Adverse litigation outcomes exceeding reserves
- Persistent inflation or supply chain disruptions
- Accelerating private label share gains in core categories
Key Debates
KVUE's 15.12x P/E expands to 18x by Q4 2024.
KVUE's -8.81% 20-day loss reverses, hitting $18 PT by Q3 2024.
KVUE maintains 2.80% Fwd Rev Growth through FY24.